Protein signal pathway mapping: Screening potential drug targets for Multiple Myeloma
Amy VanMeter(George Mason University), Lance A. Liotta(George Mason University), Christopher J. Walker(Ohio University), Julia Wulfkuhle(University of California, San Francisco), Michele Signore(Istituto Superiore di Sanità), Vineela Ayyagari(George Mason University), Valerie Calvert(George Mason University), Mariaelena Pierobon(George Mason University), Virginia Espina(George Mason University), Jianghong Deng(Capital Medical University), Rosa I. Gallagher(George Mason University), Emanuel Petricoin(George Mason University)
Cancer Research
May 1, 2008
Cited by 0
Related Papers
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
|Cancer Cell|2022|335
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
|Cancer Cell|2021|330
Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI‐TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer
|Disease Markers|2001|287
TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase
|Brain Research|1992|282